Patents by Inventor Michael Neu

Michael Neu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200011403
    Abstract: A tensioner comprising a base having a shaft, an arm pivotally engaged with the shaft, a pulley journalled to the arm, a torsion spring engaged between the arm and the base, a damping element for damping an arm movement, the damping element frictionally engaged with the arm upon a pressing engagement by the torsion spring, the arm having an anodic oxide surface finish, and the damping element frictionally engaging the anodic oxide surface finish.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 9, 2020
    Inventors: Michael Neu, Peter Helmut Wilhelm
  • Publication number: 20190211093
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 11, 2019
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Patent number: 9839797
    Abstract: A process is provided for the production of linear saturated alkanes from one or more primary alcohols, wherein the carbon chain of the one or more primary alcohols has one carbon atom more than the alkane, including conducting reductive dehydroxymethylation of one or more primary fatty alcohols containing 8 to 24 carbon atoms, at a temperature ranging from 100 to 300° C. and pressures from 1 to 250 bar in the presence of hydrogen and a catalyst, and removing water formed during the reaction.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: December 12, 2017
    Assignee: Cognis IP Management GmbH
    Inventors: Jürgen Falkowski, Markus Dierker, Michael Neuβ, Karl Heinz Schmid, Stephan Würkert, Lars Zander
  • Publication number: 20160017030
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 21, 2016
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Publication number: 20150322236
    Abstract: The invention relates to a composition, which comprises a chlorine containing thermoplastic polymer (PVC) as the substrate and a combination of a Fischer-Tropsch (FT)-wax with oxidized polyethylene wax.
    Type: Application
    Filed: February 11, 2013
    Publication date: November 12, 2015
    Applicant: BASF SE
    Inventors: Szilard CSIHONY, Yvonne HEISCHKEL, Rainer NOLTE, Michael NEUß, Bernd DUTTRA, Thomas FRIEDMANN
  • Publication number: 20140377275
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 25, 2014
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Patent number: 8821865
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: September 2, 2014
    Assignee: Abbvie Biotechnology Ltd.
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick
  • Publication number: 20140141008
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • Publication number: 20140141007
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • Patent number: 8615870
    Abstract: An installation tool to install a cruise control stop switch onto a brake pedal of an automotive vehicle includes a cylindrical shaped main body, a cylindrical shaped top portion attached to an open end of the main body, a power supply enclosed within the main body and the top portion, multiple indicators attached to an outer surface of the main body, and a removable coupler located in a recess in the top portion. The coupler, which is electrically connected to the power source and the multiple indicators, is configured to receive the cruise control stop switch.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: December 31, 2013
    Assignee: Honda Motor Co., Ltd.
    Inventors: Michael Neu, Danny Parks, David McCoy
  • Patent number: 8356696
    Abstract: A system and method for lubricating components where the lubricant is applied in mist form within a substantially enclosed cavity. The cavity contains a draining aperture which collects excess lubricant for subsequent re-use by the system. The cavity is defined by a spray head that includes a base having attached thereto a cover plate with an opening adapted to receive therethrough a component to be lubricated. The cavity and lubrication chamber prevents the escape of excess lubricant. The collection and reuse of excess lubricant provides a closed loop system that reduces lubricant waste.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: January 22, 2013
    Assignee: Honda Motor Co., Ltd.
    Inventors: Brian Carroll, Michael Neu, Chris Petty, Dudley Headley, David McCoy, Stephen Smith
  • Publication number: 20120263731
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: November 11, 2011
    Publication date: October 18, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Wolfgang Fraunhofer, Laura Redden, Susan K. Paulson, Tong Zhu, Michael Neu, Markus Tschoepe, Carsten Weber, Martin Gastens, Alexander Feick
  • Publication number: 20100278822
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: May 3, 2010
    Publication date: November 4, 2010
    Applicant: ABBOTT BIOTECHNOLOGY, LTD.
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • Publication number: 20090298917
    Abstract: The present invention related to a non-viral vector system for the delivery of nucleic acids which is modified on the basis of polyethylene imine (PEI) with polyethylene glycol (PEG) and which contains a peptide sequence with PTD/CPP-functionality. This vector system is used as gene transfer system for the epithelial cells of the bronchial tubes and alveoli of the lung. The system is highly stable, protects the DNA in the pulmonary environment, has a low zeta-potential and a low aggregation tendency in a medium with a high ionic strength. Furthermore, it is characterized by a low in vitro and in vivo cytotoxicity and allows for a very high transfection efficiency. The vector system according to the present invention is used for a transfection by inhalation in local pulmonary therapy.
    Type: Application
    Filed: May 20, 2006
    Publication date: December 3, 2009
    Inventors: Thomas Kissel, Elke Kleemann, Michael Neu, Tobias Gessler, Thomas Schmehl